BioSpace News Archive

23andMe Holding Co. announced two poster presentations on 23ME-00610, an investigational antibody targeting CD200R1, at the Society for Immunotherapy of Cancer’s 38th Annual Meeting in San Diego, CA, taking place November 1-5, 2023.

McKesson Corporation will release its second quarter fiscal 2024 financial results after market close on Wednesday, November 1, 2023.

Takeda announced that the U.S. Food and Drug Administration has approved a subcutaneous administration of ENTYVIO® for maintenance therapy in adults with moderately to severely active ulcerative colitis after induction therapy with ENTYVIO intravenous.1 ENTYVIO SC is expected to be available in the U.S. as a single-dose pre-filled pen by the end of October.

Aytu BioPharma, Inc.announced financial and operational results for the fourth quarter and fiscal year ended June 30, 2023.

Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on September 26, 2023, the Company’s Board of Directors approved “inducement” grants to 47 new employees under Rule 5635 of the NASDAQ Listing Rules.

Biophytis SA publishes its half-year accounts as of 30 June 2023 and provides an update on the progress of its R&D projects over the 1st half of the year and the last few months.

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that the Taiwan Food and Drug Administration has approved the New Drug Application for XERAVA® for the treatment of complicated intra-abdominal infections.

Antengene Corporation Limited announced that it will present five programs at the 2023 Society of Immunology in Cancer Annual Meeting to be held in San Diego from November 1-5, 2023.

Akeso, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for AK117, a next generation CD47 monoclonal antibody in combination with azacitidine for treatment of patients with newly diagnosed higher-risk myelodysplastic syndromes.

The winners were Akribion Genomics (1st place), Plantman (2nd place) and Ningaloo Biosystems (3rd place).